Cardiac involvement in Fabry disease- A non-invasive assessment and the role of specific therapies

Fabry disease is an X-linked inherited metabolic disorder due to the pathogenic mutation of the GLA gene, which codes lysosomal enzyme alpha-galactosidase A. The resultant accumulation of glycosphingolipids causes various systemic symptoms in childhood and adolescence, and major organ damage in adulthood. Cardiac involvement is important as the most frequent cause of death in Fabry disease patients. Progressive left ventricular hypertrophy with varying degrees of contractile dysfunction as well as conduction abnormalities and arrhythmias are typical cardiac features, and these findings can be evaluated in detail via non-invasive modalities, such as an electrocar-diogram, echocardiography and cardiac magnetic resonance. In addition, specific therapies of enzyme replace-ment therapy and pharmacological chaperone therapy are available, and their beneficial effects on cardiac involvement have been reported. This minireview highlights recent evidence concerning non-invasive modali-ties for assessing cardiac involvement in Fabry disease and the effects of enzyme replacement therapy and phar-macological chaperone therapy on the findings of those modalities.(c) 2022 Elsevier Inc. All rights reserved.